At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Ipilimumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of Ipilimumab in Japanese Subjects With Unresectable or Metastatic Melanoma
In Brief
A Phase 2 clinical trial evaluating Ipilimumab for Melanoma. Completed, enrolled 20 participants across 6 sites.
Detailed Summary
The purpose of this study is to assess the safety of Ipilimumab monotherapy in Japanese subjects with advanced melanoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartDec 2013
Primary CompletionMay 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedNov 25, 2013
Enrollment StartDec 1, 2013
Primary CompletionMay 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.6 years ago
Interventions
Ipilimumabbiological